BioWire Weekly - 001

Monday Morning Biotech News for the past week (28Jan - 04Feb)

Foreword:

Welcome back to our exploration of the frontiers of technology and biotechnology. Your engagement and feedback have been instrumental in shaping this Blog, showcasing a shared enthusiasm for taking deep dives into groundbreaking research and innovations. However, I want to add additional content to this substack in a shorter format that gives a broader glimpse of recent news across the biotech sectors. These topics will range from specific discoveries to general sector observations. Please join me in this new experimental format, where I will highlight some of what find to be interesting observations across Biotech.

1. Neuralink's First Human Brain Implant: Elon Musk's company, Neuralink, successfully implanted its brain-chip, Telepathy, in the first human patient. This marks a critical milestone in the company's goal to help patients overcome paralysis and various neurological conditions. Initial results showed promising neuron spike detection. A more in-depth review can be found in an article earlier published this week (linked above).

2. Thermo Fisher's 2024 Forecast: Thermo Fisher Scientific forecasted its annual profit and revenue below Wall Street estimates, indicating a continued reduction in demand for its bioprocessing services used in therapies and vaccines, particularly highlighting challenges in the biotech sector. My personal impression for Thermo is that there is a lack of appetite for the new COVID-related vaccines (vaccine fatigue) and the overall trend for the past year has been decreased investment into this space due to higher interest rates and tighter monetary policy. In addition, some of this blame may fall on the dampening expectations for demand recovery in China.

Cour Pharmaceuticals pipeline.

3. Cour Pharmaceutical's $105M Funding for Autoimmune Disease Treatment: COUR Pharmaceuticals, a clinical-stage biotechnology company focused on developing treatments for autoimmune and inflammatory diseases, recently secured $105 million in Series A financing. The funding round, co-led by Lumira Ventures and Alpha Wave Ventures, with participation from notable investors including Roche Venture Fund, Pfizer, Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund, will support the advancement of COUR's product candidates into Phase 2a clinical trials for Myasthenia Gravis and Type 1 Diabetes. Leveraging its proprietary antigen-specific immune tolerance platform, COUR aims to induce a state of immune tolerance, reprogramming the immune system to ignore specific antigens associated with autoimmune responses, thus addressing the underlying cause of immune-mediated diseases without suppressing the immune system's overall function.​

4. Breakthrough in Light-Powered Yeast for Biofuels and Cellular Aging Research: Researchers at the Georgia Institute of Technology have engineered a groundbreaking light-powered yeast, marking a significant advancement with potential applications in biofuel production, evolutionary biology, and cellular aging research. By integrating a rhodopsin gene (rhodopsin is a photoreceptor molecule) from a parasitic fungus into baker's yeast, they enabled it to utilize light for energy, enhancing growth speed under illuminated conditions. This innovation not only offers a simpler alternative to the complex mechanisms plants use for photosynthesis but also provides insights into the evolutionary adaptability of rhodopsins across diverse biological lineages. The research underscores the potential for using light-powered organisms to overcome energy limitations in multicellular evolution and opens new avenues for studying the mechanisms of cellular aging, as well as improving bioproduction processes critical for developing sustainable biofuels.​

   

5. Drug Pricing Reforms: The U.S. Department of Health and Human Services released new data highlighting that Americans pay three times more for prescription drugs than other developed countries and nearly ten times more for insulin. This revelation comes as drug pricing reforms are becoming a central issue as the 2024 election approaches. The recent initiation of formal negotiations between the US government and the pharmaceutical industry over the price of these 10 specific high-cost drugs marks a significant event that could have far-reaching implications across the biotech and Big Pharma sectors. These drugs, essential for treating cancer, diabetes, and other complex conditions, collectively cost Medicare about $50 billion annually. This move towards negotiating drug prices reflects a crucial aspect of healthcare policy to improve drug affordability and accessibility, mirroring practices in Europe, the UK, and Canada. However, concerns arise about potential impacts on pharmaceutical R&D spending, with fears that price controls could dampen innovation and slow the development of new drugs. I would personally be much happier with a less heavy-handed approach by the government and market-based incentives that create more affordable products through competition.

Support:

These newsletters take a significant amount of effort to put together and are totally for the benefit of the reader. If you find these explorations valuable, there are multiple ways to show your support:

• Engage: Like or comment on posts to join the conversation.

• Subscribe: Never miss an update by subscribing to the Substack.

• Share: Help spread the word by sharing posts with friends directly or on social media.

References:

[1] https://www.biospace.com/news/

[1] https://davidkingsley.substack.com/p/musks-neuralink-achieves-first-human

[2] https://www.reuters.com/business/healthcare-pharmaceuticals/thermo-fisher-forecasts-2024-profit-below-estimates-biotech-demand-slump-2024-01-31/

[3] https://www.startus-insights.com/innovators-guide/biotech-news-brief/

[4] https://investorplace.com/2024/01/biotech-breakthroughs-in-2024-and-the-3-stocks-that-can-benefit/

[5] https://www.biopharmadive.com/news/cour-nanoparticle-autoimmune-biotech-startup-series-a/705979/#:~:text=Biotechnology%20startup%20Cour%20Pharmaceuticals%20has,Pfizer%20and%20Bristol%20Myers%20Squibb.

[6] https://www.cell.com/current-biology/fulltext/S0960-9822(23)01744-X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS096098222301744X%3Fshowall%3Dtrue